Ventana's companion Dx to lung cancer drug wins Chinese approval

09/12/2013 | GenomeWeb Daily News (free registration)

Ventana Medical Systems received approval in China for its Ventana ALK Rabbit Monoclonal Primary Antibody test, which is used to pinpoint patients with nonsmall cell lung cancer who are positive for the anaplastic lymphoma kinase fusion gene. The assay has been approved for use as a companion diagnostic test to Pfizer's lung cancer drug Xalkori.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA